{"entity":{"id":"cradle-bio","kind":"company","name":"Cradle","aka":[],"tldr":"Cradle is a protein-engineering AI platform used by pharma to optimise antibodies and enzymes.","summary":"Cradle, based in Amsterdam and Zurich, is a protein engineering AI platform used by pharmaceutical companies to optimise antibodies and enzymes. It runs generative models over protein sequences with wet-lab feedback and raised a 73 million dollar Series B in 2024. OnCo links it to de novo designed protein binders. Whether AI-optimised antibodies show measurable advantages in the clinic over conventionally engineered ones is the open question. The de novo protein binder page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.cradle.bio"}],"tags":["ai","protein-design"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["de-novo-protein-design","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Amsterdam / Zurich","country":"NL","companyType":"ai-software","website":"https://www.cradle.bio","investors":[],"funding":[]},"route":"/companies/cradle-bio/","neighbours":{"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"de-novo-protein-design","kind":"technology","name":"De novo designed protein binders","route":"/technologies/de-novo-protein-design/"}]}}